Key Takeaways:
- Investors span beauty, healthcare, retail, biomanufacturing, and professional investment institutions.
- The diverse industrial capital will deepen upstream and downstream collaboration.
- The company targets beauty, healthcare, and nutrition markets.
L'Oréal and Walgreens Boots Alliance co-led the financing to scale AI-driven biomaterials.
WHO: Shenzhen Boyin Biotechnology, founded in 2021 by Dr. Zhong Chao and CEO Cui Junfeng from the Shenzhen Institute of Advanced Technology, combines synthetic biology and AI to design and manufacture advanced biomaterials, including recombinant mussel adhesive protein and Colamin. The company has established PAM²L, a closed-loop DBAP R&D platform that covers the entire process, from R&D to commercialization of innovative biomaterials.
WHY: The investment will upgrade its AI biomaterials R&D platform, develop new materials, scale production, and expand at home and abroad, scaling molecules from lab validation to commercial applications.
DETAILS:
- Shenzhen Boyin Biotechnology raised $27.5 million in Series A and A+ financing.
- A jointly established Walgreens-Guangzhou Pharmaceutical fund co-led the Series A round alongside L'Oréal BOLD via Shanghai Meicifang Investment Co.
- GRC SinoGreen Capital, CoStone Capital, Xingbo Shenghui, and Junke Danmu also participated in the Series A round.
- The Guangxin Fund led the Series A+ round.
- Shenzhen Boyin Biotechnology participated in L’Oréal’s 2024 BIG BANG beauty technology program.
